Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ga-68-NGUL/Lu-177-DGUL in metastatic castration-resistant prostate cancer
KCT0006160Phase 2Recruiting
- Sponsor
- CellBion
- Start
- Apr 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium-68 NGUL and Lutetium (177Lu) DGUL in metastatic castration-resistant prostate cancer (mCRPC), sponsored by CellBion. Primary endpoints: Safety and tolerability, Dosimetry and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
gallium-68 NGULLutetium (177Lu) DGUL
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on KCT0006160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006160.